Radiotherapy dose intensification for high-risk prostate cancer—what is gained?

The GETUG-AFU 18 phase 3 trial (n=505, 25 centres, France) showed that escalating radiotherapy from 70 Gy to 80 Gy alongside 3 years of androgen deprivation therapy significantly improved biochemical or clinical progression-free survival in high-risk prostate cancer, from 72.2% to 83.6% at 10 years (stratified HR 0.56, 95% CI 0.40–0.78). At 5 years, the benefit was more modest (88.1% vs 91.4%). These results support dose intensification as a meaningful strategy for this patient population.